DK0433827T3 - Cytotoksisk lumfocytmodningsfaktor - Google Patents

Cytotoksisk lumfocytmodningsfaktor

Info

Publication number
DK0433827T3
DK0433827T3 DK90123670T DK90123670T DK0433827T3 DK 0433827 T3 DK0433827 T3 DK 0433827T3 DK 90123670 T DK90123670 T DK 90123670T DK 90123670 T DK90123670 T DK 90123670T DK 0433827 T3 DK0433827 T3 DK 0433827T3
Authority
DK
Denmark
Prior art keywords
clmf
cells
proteins
relates
present
Prior art date
Application number
DK90123670T
Other languages
English (en)
Inventor
Richard Anthony Chizzonite
Maurice Kent Gately
Ulrich Andreas Gubler
Jeffrey David Hulmes
Yu-Ching Eugene Pan
Frank John Podlaski
Alvin Seth Stern
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27412641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0433827(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK0433827T3 publication Critical patent/DK0433827T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK90123670T 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor DK0433827T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45570889A 1989-12-22 1989-12-22
US52093590A 1990-05-09 1990-05-09
US57228490A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
DK0433827T3 true DK0433827T3 (da) 1998-09-28

Family

ID=27412641

Family Applications (4)

Application Number Title Priority Date Filing Date
DK97104656T DK0790255T3 (da) 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK97104682T DK0790308T3 (da) 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod
DK90123670T DK0433827T3 (da) 1989-12-22 1990-12-09 Cytotoksisk lumfocytmodningsfaktor

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK97104656T DK0790255T3 (da) 1989-12-22 1990-12-09 Monoklonale antistoffer som er rettet mod den cytotoksiske lymfocytmodningsfaktor
DK97104860T DK0790309T3 (da) 1989-12-22 1990-12-09 Cytotoksisk 40kD underenhed af lymfocytmodningsfaktor og monoklonale antistoffer rettet derimod
DK97104682T DK0790308T3 (da) 1989-12-22 1990-12-09 Cytoksisk lymfocytmodningsfaktor 35kD-underenhed samt monoklonale antistoffer rettet derimod

Country Status (11)

Country Link
EP (4) EP0790309B1 (da)
JP (2) JP3238418B2 (da)
AT (4) ATE369383T1 (da)
AU (2) AU6834990A (da)
BG (1) BG60933B2 (da)
CA (3) CA2572802A1 (da)
DE (4) DE69034244T2 (da)
DK (4) DK0790255T3 (da)
HU (1) HU211879A9 (da)
IE (1) IE904694A1 (da)
NZ (1) NZ236545A (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5456924A (en) * 1988-12-23 1995-10-10 Immunotec Research Corporation Ltd. Method of treatment of HIV-seropositive individuals with dietary whey proteins
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0375045A1 (en) * 1988-12-22 1990-06-27 Duphar International Research B.V New annelated indole derivatives
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US6830751B1 (en) 1994-03-14 2004-12-14 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of rheumatoid arthritis
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
AU695129B2 (en) * 1995-02-06 1998-08-06 Genetics Institute, Llc Formulations for IL-12
US5891680A (en) * 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
US5880146A (en) * 1995-06-07 1999-03-09 Fuji Immunopharmaceuticals Corporation Inhibition of IL-12-induced IFN-γ synthesis by specific bis-phenol compounds as a method of immune modulation
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
GB9609932D0 (en) * 1996-05-13 1996-07-17 Hoffmann La Roche Use of IL-12 and IFN alpha for the treatment of infectious diseases
WO1997046583A1 (fr) 1996-06-04 1997-12-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Nouvelle proteine de cytokine feline
AU4908197A (en) * 1996-10-18 1998-05-15 Valentis, Inc. Gene expression and delivery systems and uses
JP2001503257A (ja) * 1996-10-18 2001-03-13 バレンティス・インコーポレーテッド Ｉｌ―１２遺伝子発現および送達系および使用
US6054487A (en) * 1997-03-18 2000-04-25 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
WO1998041229A1 (en) * 1997-03-19 1998-09-24 F. Hoffmann-La Roche Ag USE OF IL-12p40 AS IMMUNOSTIMULANT
JP2002241398A (ja) * 1997-06-03 2002-08-28 Chemo Sero Therapeut Res Inst 新規なイヌサイトカインタンパク質
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU763719B2 (en) 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US7026456B1 (en) 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2380331C (en) 1999-08-09 2012-11-20 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
AU2005202420B2 (en) * 1999-09-09 2008-08-07 Merck Sharp & Dohme Corp. Mammalian cytokines; related reagents and methods
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
ATE389019T1 (de) * 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
EP1905832A3 (en) * 1999-09-09 2009-09-09 Schering Corporation Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
US7115712B1 (en) 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
RU2366664C2 (ru) 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
EA016022B1 (ru) 2004-12-21 2012-01-30 Сентокор, Инк. Выделенное антитело млекопитающего против il-12 и способ изменения его активности
ES2384055T3 (es) * 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
WO2009068630A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs
US7891807B2 (en) * 2009-06-11 2011-02-22 Ana Nichole Mansuy Decorative eyeglass temples
BR112018069776A2 (pt) 2016-03-29 2019-02-05 Janssen Biotech Inc tratamento de psoríase com intervalo de dosagem aumentado de anticorpos anti-il-12 e/ou anti-il-23
US10189151B2 (en) 2016-11-14 2019-01-29 Snap-On Incorporated Compact head body hammer
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP7421500B2 (ja) 2018-05-18 2024-01-24 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP7359845B2 (ja) 2018-09-24 2023-10-11 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
BR112021023295A2 (pt) 2019-05-23 2022-02-08 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
CA2002607C (en) * 1988-11-10 2004-01-27 Gordon G. Wong Natural killer stimulatory factor

Also Published As

Publication number Publication date
JP2002167400A (ja) 2002-06-11
DE69034244D1 (de) 2007-08-16
EP0433827A3 (en) 1992-07-01
IE990005A1 (en) 2000-11-01
CA2346997A1 (en) 1991-06-23
DK0790308T3 (da) 2007-10-08
CA2572802A1 (en) 1991-06-23
ATE369383T1 (de) 2007-08-15
DE69034247D1 (de) 2007-09-06
IE990007A1 (en) 2000-11-01
EP0790309B1 (en) 2007-07-25
EP0790255A2 (en) 1997-08-20
JP3238418B2 (ja) 2001-12-17
IE904694A1 (en) 1991-07-17
AU674363B2 (en) 1996-12-19
BG60933B2 (bg) 1996-06-28
ATE163675T1 (de) 1998-03-15
CA2032653C (en) 2002-05-28
ATE366311T1 (de) 2007-07-15
ATE368112T1 (de) 2007-08-15
DK0790255T3 (da) 2007-11-26
DE69034244T2 (de) 2008-04-03
EP0433827B1 (en) 1998-03-04
NZ236545A (en) 1993-04-28
EP0433827A2 (en) 1991-06-26
DE69034249D1 (de) 2007-09-20
JP3375949B2 (ja) 2003-02-10
DK0790309T3 (da) 2007-11-05
JPH05294999A (ja) 1993-11-09
EP0790308B1 (en) 2007-07-04
DE69034249T2 (de) 2008-05-29
EP0790255A3 (en) 2000-03-01
CA2346997C (en) 2007-02-20
AU6834990A (en) 1991-06-27
CA2032653A1 (en) 1991-06-23
EP0790255B1 (en) 2007-08-08
HU211879A9 (en) 1995-12-28
EP0790308A1 (en) 1997-08-20
DE69032086D1 (de) 1998-04-09
DE69032086T2 (de) 1998-09-17
DE69034247T2 (de) 2008-04-17
IE990006A1 (en) 2000-11-01
AU5471294A (en) 1994-06-09
EP0790309A1 (en) 1997-08-20

Similar Documents

Publication Publication Date Title
DK0433827T3 (da) Cytotoksisk lumfocytmodningsfaktor
DE69332413D1 (de) Interleukin-2 analoge mit niedriger toxizität zur verwendung in der immuntherapie
ATE105869T1 (de) Formen des koloniestimulierungsfaktors 1.
DE69007744D1 (de) Verwendung von Interleukin 2 zur Behandlung von Leukämien.
DK458889A (da) T-celle vaekstfaktor, fremgangsmaade til fremstilling deraf, farmaceutisk praeparat og detekteringsmetode og kit til brug ved detektering
GR3031927T3 (en) Cysteine depleted il-6 muteins
Nishihara et al. Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide
EP0248583A3 (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Ottmann et al. Proliferative effects of a recombinant human granulocyte colony-stimulating factor (rg-CSF) on highly enriched hematopoietic progenitor cells
Schrader et al. Molecular classification of T-cell-derived lymphokines
BG60657B2 (en) Human recombinant interleukin-2 muteins
ES8703928A1 (es) Un metodo para preparar la proteina factor de estimulacion de colonias (csf-1)recombinante